Please lik_老虎社区_美港股上老虎

mathslover74
2021-12-22

Please like

Cocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma 股价在盘前交易中飙升超过 9%</blockquote>

Cocrystal Pharma shares surged more than 9% in premarket trading. Cocrystal Pharma, Inc. announces t

Cocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma 股价在盘前交易中飙升超过 9%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":691698356,"tweetId":"691698356","gmtCreate":1640179676417,"gmtModify":1640179700208,"author":{"id":4088772072340650,"idStr":"4088772072340650","authorId":4088772072340650,"authorIdStr":"4088772072340650","name":"mathslover74","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Please like</p></body></html>","htmlText":"<html><head></head><body><p>Please like</p></body></html>","text":"Please like","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691698356","repostId":1162556937,"repostType":4,"repost":{"id":"1162556937","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640178634,"share":"https://www.laohu8.com/m/news/1162556937?lang=zh_CN&edition=full","pubTime":"2021-12-22 21:10","market":"us","language":"en","title":"Cocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma 股价在盘前交易中飙升超过 9%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1162556937","media":"Tiger Newspress","summary":"Cocrystal Pharma shares surged more than 9% in premarket trading.\nCocrystal Pharma, Inc. announces t","content":"<p>Cocrystal&nbsp;Pharma&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.</p><p><blockquote>Cocrystal Pharma 股价在盘前交易中飙升超过 9%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/870487e02f7b05efc76a12650bd3de5f\" tg-width=\"730\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Cocrystal Pharma, Inc. announces that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant. The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants including Delta, Alpha, Beta and Gamma. Cocrystal expects to initiate Phase 1 clinical studies with its COVID-19 intranasal/pulmonary protease inhibitor CDI-45205 and an oral COVID-19 protease inhibitor as rapidly as possible.</p><p><blockquote>Cocrystal Pharma，Inc.宣布，体外研究表明其口服和鼻内/肺部新型冠状病毒主要蛋白酶抑制剂对奥密克戎变种表现出抗病毒效力。该公司早些时候证实，其蛋白酶抑制剂对 SARS-CoV-2 和之前发现的所有主要变种（包括 Delta、Alpha、Beta 和 Gamma）表现出广谱抗病毒活性。Cocrystal预计将尽快启动其COVID-19鼻内/肺部蛋白酶抑制剂CDI-45205和口服COVID-19蛋白酶抑制剂的1期临床研究。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma 股价在盘前交易中飙升超过 9%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma 股价在盘前交易中飙升超过 9%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 21:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Cocrystal&nbsp;Pharma&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.</p><p><blockquote>Cocrystal Pharma 股价在盘前交易中飙升超过 9%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/870487e02f7b05efc76a12650bd3de5f\" tg-width=\"730\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Cocrystal Pharma, Inc. announces that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant. The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants including Delta, Alpha, Beta and Gamma. Cocrystal expects to initiate Phase 1 clinical studies with its COVID-19 intranasal/pulmonary protease inhibitor CDI-45205 and an oral COVID-19 protease inhibitor as rapidly as possible.</p><p><blockquote>Cocrystal Pharma，Inc.宣布，体外研究表明其口服和鼻内/肺部新型冠状病毒主要蛋白酶抑制剂对奥密克戎变种表现出抗病毒效力。该公司早些时候证实，其蛋白酶抑制剂对 SARS-CoV-2 和之前发现的所有主要变种（包括 Delta、Alpha、Beta 和 Gamma）表现出广谱抗病毒活性。Cocrystal预计将尽快启动其COVID-19鼻内/肺部蛋白酶抑制剂CDI-45205和口服COVID-19蛋白酶抑制剂的1期临床研究。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COCP":"Cocrystal Pharma, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162556937","content_text":"Cocrystal Pharma shares surged more than 9% in premarket trading.\nCocrystal Pharma, Inc. announces that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant. The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants including Delta, Alpha, Beta and Gamma. Cocrystal expects to initiate Phase 1 clinical studies with its COVID-19 intranasal/pulmonary protease inhibitor CDI-45205 and an oral COVID-19 protease inhibitor as rapidly as possible.","news_type":1,"symbols_score_info":{"COCP":0.9}},"isVote":1,"tweetType":1,"viewCount":3426,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Cocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma 股价在盘前交易中飙升超过 9%</blockquote>

评论（1）

热议股票